Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Viking Therapeutics Inc (1VT.SG)

Compare

27.36

-0.54

(-1.94%)

As of 4:42:48 PM GMT+1. Market Open.

Is Viking Therapeutics, Inc. (VKTX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other worst performing mid cap stocks to buy according to analysts. Market analysts are increasingly highlighting mid-cap stocks as a […]

Insider Monkey 3 hours ago

VKTX

^RUT
1 Biotech Stock to Buy in 2025, and 1 to Avoid

Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering. Viking Therapeutics is looking to carve out a niche thanks to VK2735, a potential anti-obesity therapy that aced phase 2 studies last year.

Motley Fool 7 hours ago

NVAX

VKTX
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Another industry also offers innovation and even game-changing products -- elements that could drive long-term returns for your portfolio. Companies in the space often focus on the research and development of cutting-edge technologies such as gene editing or messenger RNA to power the medicines of tomorrow. The "if" in the above sentence means, yes, there is risk involved in investing in biotech players, especially if they don't yet have products on the market.

Motley Fool 12 hours ago

VKTX

MRNA

CRSP
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory

We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc. (VKTX)’s share was trading at $28.32 as of Feb 25th. The obesity treatment market is undergoing a seismic shift, with demand for effective weight-loss solutions surging to […]

Insider Monkey 2 days ago

VKTX
Is Viking Therapeutics a Buy Right Now?

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug candidate that aims to compete in an area of very high demand: weight loss. The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound. Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter.

Motley Fool 2 days ago

VKTX

LLY
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect

PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.

Zacks 3 days ago

PRGO

VKTX
Viking Therapeutics (VKTX): Among the Oversold Biotech Stocks to Buy Now

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the market, […]

Insider Monkey 4 days ago

VKTX
Should You Buy VKTX Stock Amid Renewed M&A Speculations?

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.

Zacks 4 days ago

VKTX
Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Novo Nordisk stock is up around 75% despite a pullback in recent months. There's no secret to their success: Both companies have blockbuster weight-loss drugs.

Motley Fool 4 days ago

VKTX

LLY

NVO
Why Viking Therapeutics Inc. (VKTX) Surged On Friday?

We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other friday’s top gainers. The stock market suffered a bloodbath on Friday, with major indices posting whopping declines, as investors sold off […]

Insider Monkey 6 days ago

VKTX
Why Viking Therapeutics, Inc. (VKTX) Went Up On Wednesday?

We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against stocks that stand strong amid cautious market environment. The stock market showed resilience on Wednesday, with all major indices ending in the green […]

Insider Monkey 8 days ago

VKTX

^GSPC
Why Viking Therapeutics Inc. (VKTX) Went Down on Monday

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street’s major indices kicked off the trading on a positive note, all finishing in the green territory, as investors brushed off fears […]

Insider Monkey 17 days ago

VKTX

^GSPC
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and Viking Therapeutics (NASDAQ: VKTX), which is far along in its development of an advanced GLP-1-based obesity treatment. The gainer was Hims & Hers Healthcare (NYSE: HIMS).

Motley Fool 17 days ago

NVO

VKTX
2 Stocks to Buy With Less Than $40

As long as investors hold on to these companies' shares for a while and add to their positions regularly, strong returns await them. It has delivered better mid-stage results than most in the sea of prominent (and not-so-prominent) drugmakers looking to dip their toes in the fast-growing weight loss market. The company's VK2735 produced excellent data in phase 2 clinical trials.

Motley Fool 18 days ago

EXEL

VKTX
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road. If you're more of a cautious investor, you can aim for a well-established and diversified player that pays dividends and is known for steady earnings growth.

Motley Fool 18 days ago

PFE

ABT

VKTX
The M&A boom of 2025 is just getting started — and here are 5 potential targets

These companies should do well even if they’re not acquired.

MarketWatch 19 days ago

WMT

VKTX
Viking Therapeutics price target lowered to $96 from $109 at B. Riley

B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains a buyer on share weakness following the Q4 report. The analyst left the earnings call “particularly encouraged” by the oral VK2735 delivering on “injectables’-like” weight loss data, which Riley believes would be unprecedented in the space. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

TipRanks 20 days ago

VKTX
2 Stocks That Could Soar Again in 2025

Two in particular stood out: Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT). Both saw their shares more than double in 2024, thanks to strong clinical progress. Let's look deeper at Viking's and Summit's prospects this year and beyond.

Motley Fool 20 days ago

VKTX

SMMT
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss drug. Viking Therapeutics' weight management candidate could produce blockbuster sales down the road, but this isn't enough to hold the attention of a stock market obsessed with artificial intelligence (AI). When the market closed on Feb. 5, shares of Viking Therapeutics were down about 65% from the peak they reached in 2024.

Motley Fool 20 days ago

VKTX

LLY
The Drug Industry Is Having Its Own DeepSeek Moment

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S. counterparts.

The Wall Street Journal 21 days ago

VKTX

SMMT

XBI

Performance Overview

Return	1VT.SG	S&P 500
YTD	-29.30%	+0.53%
1-Year	-66.68%	+16.63%
3-Year	+824.64%	+35.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viking Therapeutics Inc (1VT.SG)

Is Viking Therapeutics, Inc. (VKTX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

1 Biotech Stock to Buy in 2025, and 1 to Avoid

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Viking Therapeutics, Inc. (VKTX): A Bull Case Theory

Is Viking Therapeutics a Buy Right Now?

Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect

Viking Therapeutics (VKTX): Among the Oversold Biotech Stocks to Buy Now

Should You Buy VKTX Stock Amid Renewed M&A Speculations?

Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk

Why Viking Therapeutics Inc. (VKTX) Surged On Friday?

Why Viking Therapeutics, Inc. (VKTX) Went Up On Wednesday?

Why Viking Therapeutics Inc. (VKTX) Went Down on Monday

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today

2 Stocks to Buy With Less Than $40

3 No-Brainer Healthcare Stocks to Buy With $200 Right Now

The M&A boom of 2025 is just getting started — and here are 5 potential targets

Viking Therapeutics price target lowered to $96 from $109 at B. Riley

2 Stocks That Could Soar Again in 2025

Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?

The Drug Industry Is Having Its Own DeepSeek Moment

Performance Overview